Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition
Kalorama has been researching and examining the development of cancer vaccines for seven years.In April 2010, the cancer vaccine market experienced one of the largest achievements for therapeutic vaccine treatment of cancer—the approval of prostate cancer vaccine PROVENGE (TM).This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was a decade a go merely a speculative area.
Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround.With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.
This Kalorama Information report - New Developments in the Cancer Vaccine Market, 2010 - focuses on both preventive and therapeutic cancer vaccines in development. Cancers with vaccine development or potential are profiled in this report, some of these include:
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market.Specifically, cancers where there is current vaccines development are profiled.Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround.With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.
This Kalorama Information report - New Developments in the Cancer Vaccine Market, 2010 - focuses on both preventive and therapeutic cancer vaccines in development. Cancers with vaccine development or potential are profiled in this report, some of these include:
- Cervical
- Colon/Rectal
- Lung
- Lymphoma
- Melanoma
- Prostate
- Breast
- Gastrointestinal
- Renal
- Brain
- Bladder
- Ovarian
- Leukemia
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market.Specifically, cancers where there is current vaccines development are profiled.Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Safety Concerns
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- Economic Conditions and Vaccine Discovery
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Disease Burden
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
Introduction
Cancer Descriptions
Timeline of Cancer Vaccine Developments
History and Growth of the Cancer Treatment Market
Types of Vaccines
Antigen/Adjuvant Vaccines
Whole Cell Tumor Vaccines
Dendritic Cell (DC) Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Types of Therapeutic Vaccines
Patient-Specific Vaccines
Prostate Specific Antigen
Sialyl Tn
Heat Shock Proteins
Ganglioside Molecules
Carcinoembryonic Antigen (CEA)
MART-1
Tyrosinase
Adjuvants
Industry Structure
Demographics and Statistics
Growing and Aging Population
Tobacco Use and Obesity Increases Cancer Risk
Tobacco Use
Obesity
Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Gardasil/Silgard
Cervarix
Description of Vaccines in Development
V503
RG3484
PV701
Lovaxin C
VGX-3100
CA-9
Market Summary
Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Overview
Description of Vaccines on the Market
OncoVAX
Description of Vaccines in Development
OncoVAX
TroVAX
CEA VRP Vaccine (AVX701)
IMA910
CDX-1307
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
GI-4000
GVAX
Oncophage
CRS-207
Lapuleucel-T
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
HyperAcute Lung
GI-4000
Oncophage
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DCVax-Lung
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
BiovaxID
MyVax
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
MVAX
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines on the Market
Provenge
Description of Vaccines in Development
DCVax-Prostate
GVAX
PROSTVAC-VF
TroVAX
Onyvax-P
MVA-BN Prostate
HyperAcute Prostate
NeuVax
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
Stimuvax
NeuVax
GVAX
AVX701 Vaccine
MVA-BN HER2
Lapuleucel-T
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Overview
Description of Vaccines in Development
GI-4000
HyperAcute Pancreas
GVAX
Oncophage
CDX-1307
ANZ-100
DCVax
Market Summary
CHAPTER ELEVEN: RENAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Oncophage
Description of Vaccines in Development
Oncophage
Reniale
TroVAX
IMA901
AGS-003
MDX-1106
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER TWELVE: BRAIN CANCER VACCINES
Overview
Glioblastoma
Neuroblastoma
Description of Vaccines in Development
DCVax-Brain
CDX-110
GliaAtak
Oncophage
Market Summary
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Overview
Description of Vaccines on the Market
BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-
Shire Pharmaceuticals)
Description of Vaccines in Development
CDX-1307
Market Summary
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Overview
Description of Vaccines in Development
Abagovomab
OVax Autologous Cell Vaccine
Lapuleucel-T
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES
Overview
Description of Vaccines in Development
GVAX-Leukemia
GRNVAC1
PR1 Peptide Vaccine
Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Safety Concerns
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS
Overview
Total Market Size and Forecast
Prophylactic versus Therapeutic Cancer Vaccine Market Size
Market and Competitor Analysis
CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES
Introduction
Accentia Biopharmaceuticals, Inc.
Antigenics, Inc.
Avax Technologies, Inc.
Dendreon Corporation
GlaxoSmithKline plc
Merck & Company, Inc.
Northwest Biotherapeutics, Inc.
Oncothyreon, Inc
Vaccinogen, Inc.
APPENDIX: COMPANY NAMES AND ADDRESSES
Introduction
Disease Burden
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
Introduction
Cancer Descriptions
Timeline of Cancer Vaccine Developments
History and Growth of the Cancer Treatment Market
Types of Vaccines
Antigen/Adjuvant Vaccines
Whole Cell Tumor Vaccines
Dendritic Cell (DC) Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Types of Therapeutic Vaccines
Patient-Specific Vaccines
Prostate Specific Antigen
Sialyl Tn
Heat Shock Proteins
Ganglioside Molecules
Carcinoembryonic Antigen (CEA)
MART-1
Tyrosinase
Adjuvants
Industry Structure
Demographics and Statistics
Growing and Aging Population
Tobacco Use and Obesity Increases Cancer Risk
Tobacco Use
Obesity
Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Gardasil/Silgard
Cervarix
Description of Vaccines in Development
V503
RG3484
PV701
Lovaxin C
VGX-3100
CA-9
Market Summary
Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Overview
Description of Vaccines on the Market
OncoVAX
Description of Vaccines in Development
OncoVAX
TroVAX
CEA VRP Vaccine (AVX701)
IMA910
CDX-1307
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
GI-4000
GVAX
Oncophage
CRS-207
Lapuleucel-T
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
HyperAcute Lung
GI-4000
Oncophage
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DCVax-Lung
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
BiovaxID
MyVax
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
MVAX
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines on the Market
Provenge
Description of Vaccines in Development
DCVax-Prostate
GVAX
PROSTVAC-VF
TroVAX
Onyvax-P
MVA-BN Prostate
HyperAcute Prostate
NeuVax
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
Stimuvax
NeuVax
GVAX
AVX701 Vaccine
MVA-BN HER2
Lapuleucel-T
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Overview
Description of Vaccines in Development
GI-4000
HyperAcute Pancreas
GVAX
Oncophage
CDX-1307
ANZ-100
DCVax
Market Summary
CHAPTER ELEVEN: RENAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Oncophage
Description of Vaccines in Development
Oncophage
Reniale
TroVAX
IMA901
AGS-003
MDX-1106
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER TWELVE: BRAIN CANCER VACCINES
Overview
Glioblastoma
Neuroblastoma
Description of Vaccines in Development
DCVax-Brain
CDX-110
GliaAtak
Oncophage
Market Summary
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Overview
Description of Vaccines on the Market
BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-
Shire Pharmaceuticals)
Description of Vaccines in Development
CDX-1307
Market Summary
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Overview
Description of Vaccines in Development
Abagovomab
OVax Autologous Cell Vaccine
Lapuleucel-T
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES
Overview
Description of Vaccines in Development
GVAX-Leukemia
GRNVAC1
PR1 Peptide Vaccine
Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Safety Concerns
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS
Overview
Total Market Size and Forecast
Prophylactic versus Therapeutic Cancer Vaccine Market Size
Market and Competitor Analysis
CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES
Introduction
Accentia Biopharmaceuticals, Inc.
Antigenics, Inc.
Avax Technologies, Inc.
Dendreon Corporation
GlaxoSmithKline plc
Merck & Company, Inc.
Northwest Biotherapeutics, Inc.
Oncothyreon, Inc
Vaccinogen, Inc.
APPENDIX: COMPANY NAMES AND ADDRESSES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
CHAPTER TWO: INTRODUCTION
Table 2- Significant Cancer Vaccine Approvals, 2000-201
Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexe
Figure 2-1 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
Figure 2-3 World Population by Selected Geographical Region, 2010-2050
Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-4 Estimated World Population by Age, 2010 and 2050
Table 2-6 Percent of Smokers by Country
Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
Table 2-7 Estimated Obesity by Country 2009 Estimates
Figure 2-6 Estimated Obesity by Country as a Portion of Total Population 2009 Estimates
Figure 2-7 Increases in Obesity by Country—2007 and 2009 Figures
Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
Figure 2-8 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2006
Figure 2-9 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of Death, All Races, Both Sexes, 2006
CHAPTER THREE: CERVICAL CANCER VACCINES
Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline
Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline
CHAPTER FIVE: LUNG CANCER VACCINES
Table 5-1 TYPES OF PRIMARY LUNG CANCER
Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
Table 5-3 Lung Cancer Vaccines in the Pipeline
CHAPTER SIX: LYMPHOMA VACCINES
Table 6-1 CLASSIFICATION OF NON-HODGKIN’S LYMPHOMAS
Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
Table 6-3 Lymphoma Vaccines in the Pipeline
CHAPTER SEVEN: MELANOMA VACCINES
Table 7-1 MALIGNANT CONDITIONS OF THE SKIN
Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
Table 7-3 Melanoma Vaccines in the Pipeline
Table 7-3 (continued) Melanoma Vaccines in the Pipeline
Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines, 2007-2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Table 8-2 Prostate Cancer Vaccines in the Pipeline
Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline
Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2015
CHAPTER NINE: BREAST CANCER VACCINES
Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Table 9-2 Breast Cancer Vaccines in the Pipeline
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline
CHAPTER ELEVEN: RENAL CANCER VACCINES
Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Table 11-2 Renal Cancer Vaccines in the Pipeline
CHAPTER TWELVE: BRAIN CANCER VACCINES
Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Table 12-2 Brain Cancer Vaccines in the Pipeline
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Table 13-2 Bladder Cancer Vaccines in the Pipeline
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Table 14-2 Ovarian Cancer Vaccines in the Pipeline
CHAPTER FIFTEEN: LEUKEMIA VACCINES
Table 15-1 TYPES OF LEUKEMIA
Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
Table 15-3 Leukemia Vaccines in the Pipeline
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Table 16-1 Cancer Detection Tests
Table 16-2 Early Safety Statistics Concerning HPV Vaccination
CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets, 2007-2015 208
Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets by Percent, 2015
CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
CHAPTER TWO: INTRODUCTION
Table 2- Significant Cancer Vaccine Approvals, 2000-201
Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexe
Figure 2-1 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
Figure 2-3 World Population by Selected Geographical Region, 2010-2050
Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-4 Estimated World Population by Age, 2010 and 2050
Table 2-6 Percent of Smokers by Country
Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
Table 2-7 Estimated Obesity by Country 2009 Estimates
Figure 2-6 Estimated Obesity by Country as a Portion of Total Population 2009 Estimates
Figure 2-7 Increases in Obesity by Country—2007 and 2009 Figures
Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
Figure 2-8 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2006
Figure 2-9 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of Death, All Races, Both Sexes, 2006
CHAPTER THREE: CERVICAL CANCER VACCINES
Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline
Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline
CHAPTER FIVE: LUNG CANCER VACCINES
Table 5-1 TYPES OF PRIMARY LUNG CANCER
Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
Table 5-3 Lung Cancer Vaccines in the Pipeline
CHAPTER SIX: LYMPHOMA VACCINES
Table 6-1 CLASSIFICATION OF NON-HODGKIN’S LYMPHOMAS
Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
Table 6-3 Lymphoma Vaccines in the Pipeline
CHAPTER SEVEN: MELANOMA VACCINES
Table 7-1 MALIGNANT CONDITIONS OF THE SKIN
Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
Table 7-3 Melanoma Vaccines in the Pipeline
Table 7-3 (continued) Melanoma Vaccines in the Pipeline
Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines, 2007-2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Table 8-2 Prostate Cancer Vaccines in the Pipeline
Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline
Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015
Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2015
CHAPTER NINE: BREAST CANCER VACCINES
Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Table 9-2 Breast Cancer Vaccines in the Pipeline
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010
Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline
CHAPTER ELEVEN: RENAL CANCER VACCINES
Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Table 11-2 Renal Cancer Vaccines in the Pipeline
CHAPTER TWELVE: BRAIN CANCER VACCINES
Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Table 12-2 Brain Cancer Vaccines in the Pipeline
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Table 13-2 Bladder Cancer Vaccines in the Pipeline
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Table 14-2 Ovarian Cancer Vaccines in the Pipeline
CHAPTER FIFTEEN: LEUKEMIA VACCINES
Table 15-1 TYPES OF LEUKEMIA
Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
Table 15-3 Leukemia Vaccines in the Pipeline
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Table 16-1 Cancer Detection Tests
Table 16-2 Early Safety Statistics Concerning HPV Vaccination
CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015
Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets, 2007-2015 208
Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets by Percent, 2015
CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES
